What to Track in an IBD Symptom Diary

An IBD symptom diary should track three layers, at three different speeds. Every day: how many times you opened your bowels compared with your own normal, whether there was blood, how urgent it was, whether it woke you, how much it hurt and how you felt overall. As things happen: doses and missed doses, steroid courses, antibiotics and painkillers, infections, emergency visits and test results. Once, then kept up to date: every IBD medicine you have ever tried, when you started and stopped it, and why it stopped. For what to write down once a flare has started, see how to track symptoms during a flare.

Most diary templates, printable journals and apps cover only the first layer. That is the layer people find easiest to keep and the one clinicians find easiest to ask about in the room. The other two are where the decisions live. When a gastroenterologist chooses what to try next, or a new specialist in a new city picks up your care, the question is rarely "how many times did you go last Tuesday". It is "what have you been on, what happened, and when".

This guide is about what goes in each layer and how to define each field so it means the same thing to you and to your team. We could find no trial comparing one IBD diary format with another in our PubMed and Europe PMC searching, so the structure below is built from what the guidelines, the clinical scores and the outcome sets actually ask for, not from a study proving this layout works best. We say so where it matters.

The short answer: three layers, and most diaries only have one

Think of the diary as three documents that happen to share a notebook or an app.

The daily log answers "how am I doing". The event log answers "what changed around then". The treatment record answers "what has already been tried, and what did it teach us". A diary that only has the first layer can show that something got worse. It usually cannot show why, and it cannot help anyone decide what to do next.

This is also where an IBD diary parts company with an IBS food diary. An IBS diary is mostly a tool for finding your own triggers, which is why our IBS food diary guide is built around meals and delay windows. IBD care is organised around controlling inflammation with treatment, so the diary's main job is to feed treatment decisions. Food can still be logged, but it is not the spine.

Layer one: the daily fields, defined the way the scores define them

Record each field in the units a clinical score already uses, and keep them separate. The scores clinicians use were built from a handful of items, and each item has a definition. If your diary uses the same definitions, anyone can read it without a translation step.

UK guidance reproduces the Mayo score, whose patient-reported items are stool frequency and rectal bleeding, and is candid about the limits of symptom measures: it notes that neither the Harvey-Bradshaw Index nor patient-reported measures correlate well with objective markers of inflammation in Crohn's disease, and treats them as complementary to endoscopy and tests rather than a substitute (Lamb 2019). The international standard set of outcomes for IBD, developed with patients, surgeons, nurses and registries, lists disease activity alongside admissions, emergency visits, treatment complications, quality of life and nutritional status (Kim 2018). That is a useful reminder that "how many times did I go" is one outcome among several.

Here is what a daily line needs, and why each field is shaped the way it is.

The Mayo bleeding wording comes straight from the table in the UK guideline, which reproduces the original 1987 scale (Lamb 2019, Schroeder 1987). The urgency, night-time frequency and wellbeing items come from the Simple Clinical Colitis Activity Index, which was designed so that activity could be judged from five clinical criteria without laboratory tests (Walmsley 1998).

We are not going to rebuild the scoring here, because other guides already do it properly. If you want to turn these fields into numbers, scoring PRO-2 for ulcerative colitis, reading a Harvey-Bradshaw Index score and scoring the SCCAI yourself each walk through one. The point of this section is narrower: if the raw fields are recorded in these shapes, any of those scores can be worked out later. If they are not, none of them can.

Why blood, urgency and frequency must stay separate

People often ask whether they really need three fields when "more trips, some blood, had to run" feels like one experience. They do, because the three move independently and mean different things. Frequency can stay up after inflammation settles, blood tends to track the lining more closely, and urgency can dominate daily life while barely registering on some scores. Our guides to blood in stool with UC and urgency cover each in depth. For diary design the lesson is simple: never merge them into one "bad day" score, because that destroys the one distinction your team most wants to see.

The number you need before you need it: your normal

The Mayo stool frequency item is not an absolute number. It is scored as how many more stools than normal you are having: one to two more, three to four more, or five or more (Lamb 2019). That makes your personal normal a load-bearing number, and it is one almost nobody writes down.

The practical consequence: while you are well, record a week or two of ordinary days and write the average at the top of your diary. That is your baseline. During a flare you will not remember it accurately, and "about twice a day, I think" is a guess that changes the score.

If you were never well long enough to know your pre-illness normal, say so rather than inventing one. "My best recent stretch averaged three a day in March" is honest and still useful. A remission baseline is also the starting point for spotting a flare early, which is its own reason to have it written down.

Why each day needs its own line

Log per day, not per week. Different scores look back over different windows. The Harvey-Bradshaw Index asks about the previous day. The Crohn's PRO-2 was derived from the CDAI diary card and uses mean daily stool frequency and pain, so it needs day-by-day entries to average (Khanna 2015). The ulcerative colitis PRO-2 takes its two items from the Mayo score (Jairath 2015). A weekly "bad week" note cannot be turned into any of them. Seven daily lines can be turned into all of them.

It is worth knowing where these instruments came from. Both PRO-2 measures were developed after the US Food and Drug Administration said patient-reported outcomes should be the primary outcome in Crohn's trials and issued guidance on their role in labelling claims, and both were derived retrospectively from data collected in drug trials. We could not read a conflict-of-interest statement for either paper through PubMed. They are good tools for recording symptoms consistently; they were built for trials, not designed as personal diaries.

The people in a large r/IBD thread about a new tracking app described exactly this recall problem: one reply explained being caught out when a clinician asked about the previous day's bowel movements, and another asked for a way to record duration, pain location and nausea against each bowel movement rather than for the day as a whole (r/IBD thread). The thread was started by the app's developer, who said so openly. The questions from other posters are the useful part.

Layer one, continued: what sits outside the gut

Add a short weekly block for the things that are not stools. They change more slowly than bowel habit, so daily sliders mostly generate noise.

• Joints, eyes, skin, mouth. A yes or no for each, with the date it started. Several of these count toward activity scores: the SCCAI adds a point per extracolonic feature, and the Harvey-Bradshaw Index scores complications such as joint pain, eye inflammation and skin lesions. Our guide to joint pain with Crohn's explains which symptoms outside the gut are recognised IBD manifestations and which tend to track gut activity. A painful red eye with blurred vision or light sensitivity is not a diary item, it is a same-day call; Crohn's and eye problems sets out why.
• Fatigue. One rating a week is enough, kept separate from pain and mood. Fatigue in IBD often persists in remission and has its own causes, from low iron to poor sleep, covered in Crohn's fatigue in remission and UC fatigue and low iron.
• Sleep. In an internet-based cohort of more than 3,000 people with IBD, people with Crohn's disease in remission whose sleep was impaired had roughly twice the odds of active disease six months later (adjusted odds ratio 2.00). No such association was seen in ulcerative colitis (Ananthakrishnan 2013). Both activity measures were self-reported short indices, and an association is not proof that poor sleep causes flares; it could equally be an early sign of one. Either way, it is cheap to note.
• Weight. Once a week, same scale, same time of day. Unintended weight loss is one of the clearest objective signals a diary can carry, and one of the easiest for a clinician to act on. Gaining weight with Crohn's covers the other direction.
• Mood or stress. One word or one number. Stress and IBD activity influence each other in both directions, which our guide to stress and Crohn's flares unpacks.
• Periods. If you menstruate, mark the days. In a questionnaire study of 49 women with ulcerative colitis, 49 with Crohn's and 90 healthy controls, women with Crohn's were more likely to report increased bowel symptoms during menstruation, and all the bowel-disease groups reported cyclical bowel habit more often than controls (Kane 1998). It was retrospective, relying on recall, which is precisely the gap a diary fills. Why Crohn's can feel worse on your period covers the evidence properly.

Layer two: the event log

The event log is a dated list of things that happened to you, entered when they happen. It is what turns a line on a chart into an explanation. A symptom spike means one thing if you started ibuprofen for a sprained knee that week, something else if you were three days late with an injection, and something else again if the whole household had a stomach bug.

In a small r/IBD thread asking how to keep track of symptoms before a gastroenterology appointment, one of the most practical replies described exactly this: a spreadsheet of food and bathroom trips, plus a note of "noteworthy events" such as a period starting or how many days it had been since the last infusion (r/IBD thread).

Here is what belongs in it.

Doses, including the product name

For every infusion, injection or change in a tablet, write the date and the product. Include the brand name, not just the drug, because many people are moved from an originator biologic to a biosimilar, or between biosimilars, and the change is easy to forget by the next appointment.

That is not because switching is known to cause trouble. In the NOR-SWITCH trial, funded by the Norwegian Ministry of Health, 482 people on stable infliximab were randomised to stay on the originator or switch to the biosimilar CT-P13. Disease worsening occurred in 26% of the originator group and 30% of the switch group, which met the trial's prespecified non-inferiority margin, and adverse events were similar (Jørgensen 2017). The trial pooled six diseases and was not powered to show non-inferiority in any single one. The same investigators later noted that a Crohn's subgroup in the main trial "displayed a close to significant difference favouring originator infliximab", then ran exploratory analyses across the main and extension trials and found no differences in activity scores, CRP, calprotectin, drug levels or antibodies in either Crohn's or colitis (Jørgensen 2020). Several of the 2020 authors report personal fees from drug manufacturers, including the biosimilar's maker.

So the reason to write the brand down is bookkeeping, not suspicion. If something does change, you and your team can line it up with the date. Do not refuse or change a product on the strength of your diary alone; bring it to your team.

"Is it wearing off?": log where you are in the cycle

If symptoms seem to return before your next dose, write down how many days after the last dose they started, every cycle. One entry is an anecdote. The same pattern across three or four cycles is a reason to ask your team a specific question.

This is one of the most common experiences people describe. In an r/CrohnsDisease thread titled "I think my remicade is wearing off", the poster described more bowel movements, urgency and some pain returning about a week before a scheduled infusion. Replies ranged from people whose teams shortened the interval, to one person on a doubled dose who still felt worse before each infusion while their trough levels looked fine, to another who had been on four biologics and felt there was no rhyme or reason to the pattern (r/CrohnsDisease thread).

That spread is the honest picture. Your diary cannot tell you whether a drug is wearing off. What answers that question is measuring the drug. UK guidance suggests that the options after anti-TNF failure (a higher dose, a shorter interval, a different anti-TNF or a different class of drug) may be informed by the clinical context and by measuring drug and anti-drug antibody levels (Lamb 2019). The American Gastroenterological Association suggests "reactive" drug monitoring, meaning a level checked because disease is active, for adults with active IBD on anti-TNF therapy. It rated that a conditional recommendation on very low quality evidence, and made no recommendation either way on routine "proactive" monitoring when disease is quiet (Feuerstein 2017). The guideline authors disclosed no conflicts.

We could find no study measuring how often patient-reported end-of-cycle symptoms line up with low drug levels. So treat your cycle notes as the reason to ask for a test, not as the answer. When the result comes back, add it to the event log with the date and where you were in the cycle when the blood was taken.

Missed, late or changed doses

Write them down without judgement. A missed or late dose is one of the most useful things a diary can surface, because it is one of the few explanations for a change that is easy to act on. Our UC tracking guide covers the adherence evidence. The diary's job is simply to make it visible.

Steroid courses: start, stop, and whether the taper held

Log every course of steroids with its start date, its stop date, and whether symptoms came back during or soon after the taper. Include courses from urgent care, a GP or a hospital stay, not just ones from your IBD team, and include rectal steroids and budesonide as well as prednisolone.

This is not bookkeeping for its own sake. UK guidance uses steroid history to define whether treatment is working:

• Steroid dependency: being unable to get below 10 mg of prednisolone within three months without symptoms returning, or relapsing within three months of stopping.
• Steroid excess: two or more courses of steroids in a year.

Both definitions come straight from the British Society of Gastroenterology guideline, which also recommends that people with ulcerative colitis on high-dose mesalazine who needed two or more steroid courses in the past year, or who become steroid-dependent or refractory, need their treatment escalated (Lamb 2019). A count of courses is therefore one of the few diary numbers that maps directly onto a guideline decision point. That decision is your team's to make, not the diary's, but they cannot make it if nobody knows there were two courses.

The numbers suggest this is not rare. In a UK audit of 2,385 outpatients across 19 centres, 28% had received steroids in the preceding 12 months and 14.8% met the definition for steroid excess or dependency. Reviewers judged the excess avoidable in 50.7% of those cases (Selinger 2019). The study received funding from AbbVie, which makes an anti-TNF drug, and it found anti-TNF maintenance associated with less steroid excess in Crohn's disease; we note that because it is relevant to how you might read that particular finding. An earlier UK audit of 1,176 patients, cited in the guideline, found 14.9% (Lamb 2019). Two separate audits, about one in seven both times.

Other medicines: painkillers and antibiotics

Note every course of antibiotics and any anti-inflammatory painkillers such as ibuprofen or naproxen, with dates and roughly how often.

The painkiller evidence is more nuanced than "NSAIDs cause flares". In a US internet cohort of 791 people in remission, people with Crohn's disease who used NSAIDs five or more times a month were more likely to have active disease six months later (23% versus 15%, adjusted relative risk 1.65). There was no such association in ulcerative colitis (22% versus 21%), and less frequent NSAID use was not associated with active disease in either condition. Regular paracetamol (acetaminophen) use was also associated with active Crohn's, which led the authors to suggest NSAID use might be a marker of a less robust remission rather than purely a cause (Long 2016). That is exactly why the dates matter: whether the painkillers came before the symptoms or after them is the question, and only a dated log can answer it.

This is not advice to stop or avoid any medicine. If pain relief is part of your life, ask your IBD team what they would prefer you use, and log what you take.

Infections, illness and emergency visits

Log stomach bugs in the household, fevers, chest infections and anything that needed antibiotics, plus every emergency department visit or admission. Two reasons. First, an infection can mimic a flare, which is why UK guidance calls for stool cultures and a Clostridioides difficile test in people presenting with suspected ulcerative colitis and in acute severe colitis (Lamb 2019). A dated note of who else in the house was ill helps your team decide what to test. Second, emergency visits and admissions are themselves outcomes in the international standard set, alongside treatment-related complications (Kim 2018). If you are on immunosuppressants, fevers and night sweats have their own considerations, which Crohn's and night sweats covers. If you have a stoma, how to track food triggers with an ostomy covers what to log once stool form stops being useful.

Test results, with dates

Every calprotectin, CRP, haemoglobin, ferritin, vitamin level and drug level, with the date and, for drug levels, where you were in your dosing cycle. The core outcome set developed through an international Delphi process names haemoglobin, CRP and faecal calprotectin as its three biomarkers, and recommends PRO-2 and the IBD-Control questionnaire at every contact with an IBD practitioner (Fierens 2024). That consensus included 13 industry representatives among its 136 stakeholders, was funded partly through a public-private European research initiative with pharmaceutical industry partners, and two of its authors are employees of a drug manufacturer. None of that makes a short questionnaire plus three routine tests an unreasonable minimum, but it is worth knowing who was in the room.

Calprotectin in particular behaves in ways that surprise people, so if yours are in the diary, our guides to what calprotectin levels mean in UC and a high calprotectin with no symptoms are worth reading before you draw conclusions from a single number.

Layer three: the treatment record that follows you

This is the part almost no diary template includes, and the part that matters most when care changes hands. It is a single page, updated after each appointment, that answers the questions every new clinician asks. If you only build one layer properly, a strong case can be made for this one, because it is the hardest to reconstruct later and the least likely to be complete in any single hospital's records if you have moved.

A few of those need expanding.

Symptom onset date. UK guidance recommends that people with colonic IBD be offered colonoscopy 8 years after symptom onset to screen for dysplasia and decide the surveillance interval, and notes that surveillance should begin 8 years after diagnosis or after symptom onset where there was a significant delay before diagnosis. People with primary sclerosing cholangitis should have surveillance from diagnosis (Lamb 2019). If your symptoms began years before anyone gave them a name, that date is the one that counts, and you may be the only person who knows it.

Pre-treatment screening. The UK guideline's pre-treatment checklist covers history of specific infections (herpes simplex, chickenpox and shingles, tuberculosis), immunisation status, tuberculosis screening before anti-TNF therapy, TPMT before thiopurines, and blood tests for hepatitis B and C, HIV and chickenpox immunity (Lamb 2019). The AGA guideline likewise suggests routine TPMT testing before starting thiopurines (Feuerstein 2017). Knowing your results and dates saves repeating tests and, more importantly, saves weeks when a new drug is being considered.

Vaccinations and screening. The American College of Gastroenterology's preventive-care guideline says documentation of up-to-date vaccinations is crucial because people with IBD are often on long-term immunosuppression, and covers the timing of vaccines along with osteoporosis, cervical and skin cancer screening. It stresses that these need coordinating between the gastroenterology team and primary care (Farraye 2017). When two teams each assume the other is keeping track, your record may be the only complete one.

Why "the reason it stopped" is the most valuable line you can write

For every IBD medicine you stop, write one sentence on why: it never worked, it worked and then stopped working, it caused a side effect, or something else (cost, pregnancy plans, your choice). Clinicians use these categories, and they are not interchangeable.

UK guidance says failure of anti-TNF therapy should be divided into primary non-response, meaning it never worked during induction, and secondary loss of response, meaning it worked and then faded. For primary non-response to one anti-TNF, the guideline says the chance of responding to a second is small and that switching to a drug with a different mechanism is more likely to succeed (Lamb 2019).

The numbers behind that are striking. In a systematic review and meta-analysis of 46 studies, a second anti-TNF after infliximab in Crohn's disease induced remission in 61% of people whose first drug had been stopped because of intolerance, 45% after secondary failure and 30% after primary failure. Response rates followed the same order: 72%, 62% and 53% (Gisbert 2015). Most of the Crohn's data (32 of 37 studies) came from people switching from infliximab to adalimumab, and we could not read a conflict-of-interest statement for the review. But the direction is consistent with the guideline, and it makes the point. "Humira didn't work" and "Humira worked for two years, then stopped" are different sentences that lead to different conversations.

And most people on long-term biologics will eventually need that history. A review of 16 studies covering 2,236 people with Crohn's disease on infliximab found that 37% lost response over follow-up, and calculated the annual risk of losing response at 13% per patient-year (Gisbert 2009). That arithmetic checks out: 37% of 2,236 is about 827 people, and 827 divided by the 6,284 patient-years of follow-up is about 13%.

One caution. Whether a drug counts as primary or secondary failure is a clinician's judgement, often made with drug levels, and people sometimes remember it differently from how it was recorded. Write down what happened, in plain words and with dates, and let your team classify it. "Felt better by week 6, symptoms back by month 14, level was low with antibodies" is more useful than a label.

A worked example: the same eighteen months, two diaries

This is an illustrative example, not a real patient. Imagine someone with Crohn's disease on a fortnightly injection, who keeps a diary for eighteen months and brings it to a new gastroenterologist after moving.

Diary A has only the daily layer. It is beautifully kept: stool counts, pain, a wellbeing emoji, some meals. The chart shows three rough patches. The new gastroenterologist can see that things were bad three times. They cannot see why, and the first ten minutes of the appointment go on questions the diary cannot answer. When did you start this injection? What were you on before? Why did you stop it? Any steroids? Any levels checked?

Diary B has the same daily layer, plus an event log and a one-page treatment record. Now the three rough patches read differently:

• Patch one lines up with a week of daily ibuprofen for a knee injury. Symptoms settled within a fortnight of stopping it. It may have been the ibuprofen, or the ibuprofen may have been a marker of something else, but the timing is on the page.
• Patch two follows a household stomach bug. A stool test was negative for C. difficile. It settled without a treatment change.
• Patch three is different. For the last four injection cycles, symptoms crept back from about day 10 of 14. A steroid course was started in month 15 by an urgent-care doctor, and symptoms returned within three weeks of finishing it. That was the second course in twelve months. No drug level has been checked.

The treatment record adds: symptoms first began two years before diagnosis; a previous thiopurine was stopped after six weeks because of pancreatitis (a side effect, not a failure to work); TPMT was normal; TB and hepatitis B screening were done at diagnosis.

Diary B does not tell the gastroenterologist what to do. It does let them see, in two minutes, a recurring end-of-cycle pattern that deserves a drug level, two steroid courses in a year, and a previous drug that stopped for intolerance rather than inefficacy. Those are the facts a treatment decision starts from. Diary A has the same person's same eighteen months, and almost none of that information.

What to leave out, or at least move to the back

Leave out anything you cannot sustain, and anything that will not change a decision. A diary that collapses in week three helps nobody.

• A dozen daily sliders. Stress, mood, energy, bloating, gas, sleep, nausea, appetite, hydration, focus: each feels relevant, and together they turn a one-minute entry into a five-minute one. Move most of them to weekly, or drop them.
• Food, as a default. Food can matter in IBD, but whether a particular food triggers inflammation is a much harder question than whether it makes you feel worse, and informal trigger-hunting generates false positives. Can food trigger a UC flare and our Crohn's food diary guide cover this properly. If you log food, do it for a defined question over a defined period, ideally with a dietitian, not forever.
• Raw logs at appointments. Bring a summary. What a clinician will actually read is its own topic, and the short version is one page, not forty.

The r/IBD thread about a note-taking app, posted by one of its co-founders, drew a top reply asking whether the information would be shared (r/IBD thread). That question belongs in this section too. A treatment record contains your whole medical history. Whatever you keep it in, know who can see it and make sure you can export it. Our guide to IBD tracker apps goes through what to check before you commit.

How often, and for how long

Daily entries, every day, in under a minute. Weekly entries once a week. Events as they happen. The treatment record after every appointment. And keep the treatment record for life.

How long to keep the daily layer is less clear. There is no evidence-based answer that we could find. A reasonable pattern is to keep it continuously while anything is changing (a new drug, a taper, a suspected flare), and to drop to a lighter version in stable remission, such as the three or four core fields, while keeping the event log and treatment record going regardless. The baseline you recorded when well is worth repeating once a year, because your normal can shift after surgery, with age, or after a long remission.

The strongest evidence that a written record plus a plan speeds things up comes from a different intervention. In a randomised trial of 203 people with ulcerative colitis, those given self-management training and a personalised plan, with follow-up on request, had relapses treated within a mean of 14.8 hours compared with 49.6 hours in the usual-care group, and made fewer hospital visits (0.9 versus 2.9 per patient per year). Quality of life did not differ (Robinson 2001). The intervention was training and an agreed plan with the clinical team, not a diary, so this does not show that diaries improve outcomes. It does show why knowing your own pattern, and having a route to act on it agreed in advance, matters. UK guidance now suggests offering guided self-management with education and written or electronic personalised information to people who want it (Lamb 2019). If your team offers a written flare plan, the date you started it belongs in the event log.

If you would rather not build this yourself, a tracker that keeps doses, symptoms and results together helps. Clairop's GI visit report puts an activity score, bowel pattern, medication adherence and labs on one page; how it works shows what it logs. Whatever you use, the three layers are what matter, not the tool.

If you have a stoma or a pouch

Most of the daily layer does not transfer, and you should not force it to. The activity scores above were built for people with an intact colon, and the Bristol stool scale does not describe stoma output. One person in the r/IBD tracker thread with a stoma asked exactly this, whether there was a different way of recording it (r/IBD thread).

Instead, track what your stoma or pouch team uses: number of emptyings, output consistency, night-time emptying, signs of dehydration, and any blood or pain. For an ileostomy, output that stops or becomes watery with cramping is a reason to call, not to log and wait; foods that can cause an ileostomy blockage covers the warning signs. The event log and the treatment record apply unchanged, and arguably matter more, because surgery changes what every later symptom means.

Myths about IBD symptom diaries

"More detail is always better." Detail you stop recording in week three is worse than a short record you keep for a year. The best-designed clinical measures are short on purpose.

"If my diary looks good, my disease is fine." Symptoms and inflammation can disagree in both directions. A clean diary is reassuring, not proof, which is why the event log holds your test results alongside your symptoms. UC symptoms in remission explores the gap from the other side.

"The diary can tell me my drug is wearing off." It can show a pattern that makes the question worth asking. The answer comes from a drug level and your team's judgement.

"My hospital has all of this already." Some of it, in some systems. If you have moved, changed hospitals, had care in urgent care or primary care, or been treated across borders, no single record may hold the whole history. Your one page can.

"A period tracker, a food app and a notes file add up to an IBD diary." They can hold pieces. The pieces that matter most in IBD, doses, steroid courses, results and the treatment history, are usually the pieces those tools have nowhere to put, as people in r/IBD discovered when a period-tracker suggestion came up (r/IBD thread).

"I should change my treatment based on what my diary shows." No. The diary is the evidence you bring to your team. Any change to a medicine, a dose or a schedule is a decision to make with them.

When to stop logging and contact your IBD team

A diary is for trends. Some changes should not wait for a trend. See a doctor promptly, rather than recording and watching, if you notice any of the red flags in the box above, or new symptoms outside the gut that are severe or sudden. Contact your IBD team at their usual route if your daily log shows a sustained change from your baseline over several days, if you have needed steroids and your symptoms come back during or soon after the taper, or if an end-of-cycle pattern repeats across several doses.

When you call, you will not need to guess. You will have the number of stools against your normal, the bleeding grade, the date the change started, what else happened that week, and what you have been on. That is what a symptom diary is for.

The short version

Track three layers. A short daily log in the shapes the clinical scores use, with your normal written at the top. A dated event log of doses, steroids, painkillers, antibiotics, infections, emergency visits and test results. And a single-page treatment record of every IBD medicine you have tried, when, and why it stopped, alongside your symptom onset date, screening results, vaccinations, scopes and surgeries. The first layer tells your team how you are. The second tells them why. The third tells them what has already been tried, which is where every next decision begins.